Clinical Trial Update: Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer [Phase 1]

View source ↗

Summary

This document provides an update on a completed Phase 1 study of abiraterone acetate in castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Prostatic Neoplasms | Phase 1 | Status: COMPLETED